Baird R W cut shares of Medpace (NASDAQ:MEDP – Free Report) from a strong-buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports.
Other analysts have also recently issued reports about the company. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Tuesday. UBS Group downgraded Medpace from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $420.00 to $350.00 in a report on Friday, September 27th. Redburn Atlantic began coverage on shares of Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective on the stock. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and lowered their target price for the company from $415.00 to $345.00 in a report on Wednesday, September 25th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $380.00.
Read Our Latest Stock Report on Medpace
Medpace Trading Up 0.7 %
Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. During the same quarter in the prior year, the business earned $2.22 EPS. Medpace’s quarterly revenue was up 8.3% compared to the same quarter last year. Research analysts predict that Medpace will post 11.77 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in MEDP. Sunbelt Securities Inc. grew its holdings in shares of Medpace by 24.5% in the 1st quarter. Sunbelt Securities Inc. now owns 514 shares of the company’s stock worth $208,000 after acquiring an additional 101 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in Medpace by 16.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 10,340 shares of the company’s stock valued at $4,179,000 after purchasing an additional 1,446 shares during the last quarter. State of Michigan Retirement System increased its position in shares of Medpace by 1.8% in the first quarter. State of Michigan Retirement System now owns 5,699 shares of the company’s stock valued at $2,303,000 after buying an additional 100 shares in the last quarter. Norden Group LLC increased its position in shares of Medpace by 488.0% in the first quarter. Norden Group LLC now owns 29,480 shares of the company’s stock valued at $11,914,000 after buying an additional 24,466 shares in the last quarter. Finally, Arcus Capital Partners LLC raised its position in Medpace by 15.7% during the first quarter. Arcus Capital Partners LLC now owns 965 shares of the company’s stock worth $390,000 after acquiring an additional 131 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.
Medpace Company Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
See Also
- Five stocks we like better than Medpace
- What is a Stock Market Index and How Do You Use Them?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Is WallStreetBets and What Stocks Are They Targeting?
- MarketBeat Week in Review – 10/21- 10/25
- How Investors Can Find the Best Cheap Dividend Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.